BACKGROUND: The focus of studies on cyclooxygenase-2 (COX-2) have been on its ability to mediate the biological behavior of human tumors including tumorigenesis, tumor progression, apoptosis, and differentiation. The aim of the current study was to elucidate a further finding on the clinicopathologic significance of immunohistochemical expression of COX-2 in esophageal squamous cell carcinoma (ESCC). METHODS: The immunohistochemical expression of COX-2 was examined for 76 specimens of ESCC and the correlation of COX-2 expression with clinicopathologic features was examined. RESULTS: Twenty-eight ESCCs (36.8%) had a strong expression of COX-2. The proportion of poorly differentiated SCCs among tumors with a strong expression of COX-2 (42.8%, 12 of 28) was significantly higher than that among tumors with a weak expression of COX-2 (16.7%, 8 of 48; P = .037). The depth of the tumors (P = .003) and the stage of the tumors (P = .015) were advanced significantly more progressively in ESCCs with a strong COX-2 expression. Univariate analysis showed that the prognosis of patients with ESCCs with a strong COX-2 expression was significantly poorer than that of patients with ESCCs with a weak COX-2 expression (P = .017). Multivariate analysis showed that only such tumor-related factors as lymphatic invasion (P = .004), venous invasion (P = .003), and stage of the tumors (P = .021) were found to be associated independently with worse prognosis of the patients with ESCC. CONCLUSIONS: Strong expression of COX-2 is correlated with tumor progression and poor differentiation in ESCC.
BACKGROUND: The focus of studies on cyclooxygenase-2 (COX-2) have been on its ability to mediate the biological behavior of humantumors including tumorigenesis, tumor progression, apoptosis, and differentiation. The aim of the current study was to elucidate a further finding on the clinicopathologic significance of immunohistochemical expression of COX-2 in esophageal squamous cell carcinoma (ESCC). METHODS: The immunohistochemical expression of COX-2 was examined for 76 specimens of ESCC and the correlation of COX-2 expression with clinicopathologic features was examined. RESULTS: Twenty-eight ESCCs (36.8%) had a strong expression of COX-2. The proportion of poorly differentiated SCCs among tumors with a strong expression of COX-2 (42.8%, 12 of 28) was significantly higher than that among tumors with a weak expression of COX-2 (16.7%, 8 of 48; P = .037). The depth of the tumors (P = .003) and the stage of the tumors (P = .015) were advanced significantly more progressively in ESCCs with a strong COX-2 expression. Univariate analysis showed that the prognosis of patients with ESCCs with a strong COX-2 expression was significantly poorer than that of patients with ESCCs with a weak COX-2 expression (P = .017). Multivariate analysis showed that only such tumor-related factors as lymphatic invasion (P = .004), venous invasion (P = .003), and stage of the tumors (P = .021) were found to be associated independently with worse prognosis of the patients with ESCC. CONCLUSIONS: Strong expression of COX-2 is correlated with tumor progression and poor differentiation in ESCC.
Authors: Peter Sminia; T Rianne Stoter; Paul van der Valk; Paula H M Elkhuizen; Thea M Tadema; Gitta K Kuipers; W Peter Vandertop; M Vincent M Lafleur; Ben J Slotman Journal: J Cancer Res Clin Oncol Date: 2005-10-20 Impact factor: 4.553
Authors: Susan Li Er Loong; Jacqueline Siok Gek Hwang; Hui Hua Li; Joseph Tien Seng Wee; Swee Peng Yap; Melvin Lee Kiang Chua; Kam Weng Fong; Terence Wee Kiat Tan Journal: Radiat Oncol Date: 2009-07-10 Impact factor: 3.481
Authors: K J Schmitz; R Callies; J Wohlschlaeger; R Kimmig; F Otterbach; J Bohr; H-S Lee; A Takeda; K W Schmid; H A Baba Journal: J Clin Pathol Date: 2006-02-23 Impact factor: 3.411
Authors: Pradeep Bhandari; Adrian C Bateman; Raj L Mehta; Bernard Sf Stacey; Penny Johnson; Ian A Cree; Federica Di Nicolantonio; Praful Patel Journal: BMC Cancer Date: 2006-05-19 Impact factor: 4.430
Authors: Oliver Driemel; Johanna Rieder; Christian Morsczeck; Stephan Schwarz; Samer George Hakim; Urs Müller-Richter; Torsten Eugen Reichert; Hartwig Kosmehl Journal: Mund Kiefer Gesichtschir Date: 2007-07-20